Growth Hormone Deficiency in Mild Traumatic Brain Injury
Launched by UNIVERSITY OF CALGARY · Dec 13, 2022
Trial Information
Current as of February 05, 2025
Unknown status
Keywords
ClinConnect Summary
Annually, over 250,000 Canadians and over 40 million individuals worldwide will suffer an uncomplicated concussion (head injury with no intracranial abnormalities seen on imaging). Most individuals will recover within weeks of injury but over 30% will have persistent profound symptoms (PPCS) that impedes daily function, work and social activities. To date, there are few evidence-based treatments available for patients suffering PPCS leaving patients and clinicians grasping for answers to improve health. The culminative numbers of Canadians that are living with PPCS following a concussion ar...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Sustained a concussion according to the American Congress of Rehabilitation Medicine criteria with persistent symptoms 6-months following concussion
- • Peak growth hormone of \< 3 mcg/L following glucagon stimulation test
- Exclusion Criteria:
- • Untreated pituitary dysfunction
- • Moderate/severe TBI
- • Intracranial abnormalities
- • Chronic neurologic conditions
Trial Officials
Chantel T Debert, MD, MSc
Principal Investigator
University of Calgary
About University Of Calgary
The University of Calgary is a leading research institution dedicated to advancing health and science through innovative clinical trials. With a strong emphasis on multidisciplinary collaboration, the university's clinical research initiatives aim to address pressing health challenges and improve patient outcomes. The institution fosters a robust environment for academic inquiry, leveraging state-of-the-art facilities and a diverse network of experts in various fields. Committed to ethical research practices and community engagement, the University of Calgary strives to translate scientific discoveries into tangible benefits for society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials